Skip to main content
ACRV
NASDAQ Life Sciences

Acrivon Buys Phase 2-Ready Oral JAK1 Inhibitor, Expands Into Immunology

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.57
Mkt Cap
$67.28M
52W Low
$1.27
52W High
$3.56
52W Position info
24% above low
Off High info
56% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ACRV sits 24% above its 52-week low of $1.27.

Summary

Acrivon acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, plus a preclinical PKCθ program from Aqilion AB for undisclosed cash with no future royalties or milestones. The deal adds a clinical-stage immunology and inflammation pillar alongside its oncology pipeline and comes with a concurrent termination of Aqilion's prior royalty and milestone obligations to LEO Pharma on ACR-525. Acrivon's AP3 profiling against six approved JAK inhibitors and dupilumab characterized ACR-525 as highly selective with minimal off-target effects, and the company is targeting eosinophilic esophagitis as the first indication using a formulation built for patients with difficulty swallowing. The terms are undisclosed, so the cash outlay and dilution risk are unknown, but the no-royalty, no-milestone structure keeps future obligations off the books. Acrivon had $90.0M in cash as of Q2 expected to fund operations into Q4 2027, so the purchase price matters for how much runway is consumed. A KOL webcast on November 10, 2026 at 4:00 p.m. ET will detail the ACR-525 and PKCθ programs.

At the time of this announcement, ACRV was trading at $1.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $1.27 to $3.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ACRV - Latest Insights

ACRV
Nov 06, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.63 info
Change: +$0.030 (+2%) info
Market Cap: $68.994M info
ACRV
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.63 info
Change: -$0.090 (-5%) info
Market Cap: $68.994M info
ACRV
Aug 05, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.57
Real-time Price: $1.63 info
Change: +$0.060 (+4%) info
Market Cap: $68.994M info
ACRV
Jun 17, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.52
Real-time Price: $1.63 info
Change: +$0.110 (+7%) info
Market Cap: $68.994M info
ACRV
May 22, 2026, 4:05 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.75
Real-time Price: $1.63 info
Change: -$0.120 (-7%) info
Market Cap: $68.994M info